GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rebus Hldgs Inc (OTCPK:RBSH) » Definitions » Earnings Yield (Joel Greenblatt) %

Rebus Hldgs (Rebus Hldgs) Earnings Yield (Joel Greenblatt) % : 74.07% (As of Jun. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Rebus Hldgs Earnings Yield (Joel Greenblatt) %?

Rebus Hldgs's Enterprise Value for the quarter that ended in Jun. 2023 was $0.80 Mil. Rebus Hldgs's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $0.59 Mil. Rebus Hldgs's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2023 was 74.07%.

The historical rank and industry rank for Rebus Hldgs's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

RBSH' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -210099.7   Med: 0   Max: 99999999.99
Current: 192.31

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Rebus Hldgs was 99999999.99%. The lowest was -210099.70%. And the median was 0.00%.

RBSH's Earnings Yield (Joel Greenblatt) % is ranked better than
99.78% of 1394 companies
in the Biotechnology industry
Industry Median: -15.435 vs RBSH: 192.31

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Rebus Hldgs's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Rebus Hldgs Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Rebus Hldgs's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rebus Hldgs Earnings Yield (Joel Greenblatt) % Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.28 -5.38 -232.56 3,333.33 -175.44

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 555.56 -185.19 -175.44 -114.94 74.07

Competitive Comparison of Rebus Hldgs's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Rebus Hldgs's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rebus Hldgs's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's Earnings Yield (Joel Greenblatt) % falls into.



Rebus Hldgs Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Rebus Hldgss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2022 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-0.951/0.54599675
=-174.18 %

Rebus Hldgs's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59 Mil.



Rebus Hldgs  (OTCPK:RBSH) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Rebus Hldgs Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Rebus Hldgs's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rebus Hldgs (Rebus Hldgs) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.
Executives
John Robison Montgomery director 7647 BIRCHWOOD HILL RD, CROZET VA 22932
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
Claire Thom director 31200 VIA COLINAS, #200, WESTLAKE VILLAGE CA 91362
Ronald L Shazer officer: Chief Medical Officer C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Christopher P. Lowe director, officer: President and CEO 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Scott Varde Ogilvie director 10880 WILSHIRE BLVD, SUITE 950, LOS ANGELES CA 90024
Bo Jesper Hansen director BIRKENWEG 16, MEGGEN V8 6045
Peter E Grebow director 41 MOORES ROAD, FRAZER PA 19355
Craig A Dionne director, 10 percent owner, officer: CEO,CFO, President 9901 IH 10 WEST, SUITE 800, SAN ANTONIO TX 78230
Russell Richerson 10 percent owner, officer: COO, Secretary 2511 N LOOP 1604 W, SUITE 204, SAN ANTONIO TX 78258
Kihong Kwon 10 percent owner 1015 E. CHAPMAN AVE, SUITE 201, FULLERTON CA 92831